Commentary: Clinical characteristics of male prolactinoma patients mainly presenting with severe obesity and the metabolic response to dopamine agonist therapy

Front Endocrinol (Lausanne). 2024 Mar 6:15:1371468. doi: 10.3389/fendo.2024.1371468. eCollection 2024.

Authors

Lukas Andereggen^{1

2}, Emanuel Christ³

Affiliations

¹ Department of Neurosurgery, Kantonsspital Aarau, Aarau, Switzerland.
² Faculty of Medicine, University of Bern, Bern, Switzerland.
³ Department of Endocrinology, Diabetology and Metabolism, University Hospital of Basel, Basel, Switzerland.

No abstract available

Keywords: dopamine agonist; male; metabolic response; obesity; prolactinoma.

Publication types

Comment

MeSH terms

Dopamine Agonists / therapeutic use
Humans
Male
Obesity / drug therapy
Obesity, Morbid* / drug therapy
Pituitary Neoplasms* / complications
Pituitary Neoplasms* / drug therapy
Prolactinoma* / complications
Prolactinoma* / drug therapy

Substances

Dopamine Agonists

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.